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Purpose: Previous studies of grafts implanted in dogs documented a time-dependent 
increase in platelet-derived growth factor (PDGF) production that correlated with 
inner-capsule thickness. The purpose of this study was to identify the cells in vascular 
grafts that produce PDGF. 
Methods: Dacron thoracoabdominal grafts were seeded with autologous endothelial cells 
(ECs), implanted in 11 beagles, and removed 'after 4 or 20 weeks. ECs and smooth 
muscle cells (SMCs) were cultured from grafts and adjacent aorta, and PDGF in the 
conditioned media was measured by radioreceptor assay. The PDGF A-chain mRNA level 
in freshly harvested cells was assessed using reverse transcriptase, followed by polymerase 
chain reaction, and expressed as a ratio of glyceraldehyde-3-phosphate dehydrogenase 
signal. Localization of PDGF A-chain and B-chain protein was also examined with 
immunohistochemical analysis. 
Results: Graft and aortic ECs in primary culture did not produce significantly different 
amounts of PDGY in 72 hours, averaging 368 + 160 and 340 -+ 81 pg /~g DNA, 
respectively. Graft SMCs in primary culture produced significantly more PDGF than 
aortic SMCs (584 + 343 and 113 -+ 94 pg/Ixg DNA, respectively; p < 0.01). Graft SMC 
PDGF secretion remained greater than aortic SMC PDGF secretion through at least six 
cell passages. PDGF A-chain mRNA levels were not significantly different for aortic or 
graft ECs. The PDGF A-chain mRNA level was significantly higher for graft SMCs than 
aortic SMCs (2.44 +- 0.67 and 1.45 -+ 0.57 pg/ixg, respectively; p < 0.03). Immunocy- 
tochemical analysis detected PDGF A-chain and B-chain protein in the ECs from both 
native aorta and graft as well as the subendothelial SMCs in the graft, but not in the 
SMCs of the native aorta. 
Conclusions: These results suggest hat graft SMCs are functionally altered, producing 
more PDGF than aortic SMCs. PDGF produced by graft SMCs may contribute to the 
development of intimal hyperplasia. (J Vasc Surg 1997;26:70-8.) 
Intimal hyperplasia is a recognized cause of late 
graft failure. It is characterized by smooth muscle cell 
(SMC) accumulation and matrix deposition and is 
most prominent at the anastomoses of prosthetic 
vascular grafts. The exact cause ofintimal hyperplasia 
is not clear, but many factors, including mechanical 
injury, altered shear stress, compliance mismatch, 
anastomotic flow disturbances, and mitogen release 
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from platclcts, lcukocytcs, and vessel wall cells, may 
play a role. 
A role for endothelial cell (EC)-derived mitogens 
in the development of graft intimal hyperplasia was 
suggested by its occurrence at anastomoses, the very 
areas first covered with endothelium, and by the 
observation that SMCs proliferated only under ECs, 
at the anastomoses, and in areas of transmural in- 
growth where SMCs followed ECs migrating into 
the graft. 1,2 Additional support for the role of EC- 
derived mitogens in graft intimal hyperplasia was the 
finding that intimal cells removed from endothelial- 
ized grafts in baboons expressed more messenger 
RNA (mRNA) for platelet-derived growth factor 
(PDGF) A-chain than native artery. 3Furthermore, in
situ hybridization revealed PDGF A-chain mRNA in 
graft ECs and SMCs. 4 Previous tudies in our labora- 
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tory demonstrated higher PDGF protein production 
in EC-seeded grafts compared with control grafts 
when removed 4 weeks after implantation, s In addi- 
tion, PDGF production correlated irectly with EC 
coverage, suggesting that ECs were the sourceofthe 
PDGF. 5 Interestingly, PDGF production continued 
to increase when measured in grafts halwested at 20 
and 52 weeks; however, it did not correlate with EC 
coverage but corresponded with the appearance of 
SMCs in the inner capsule. 6,7 This finding suggested 
that a significant source of PDGF production i  20- 
and 52-week grafts might be cells other than ECs. 
The purpose of this work was to identify the graft 
cells that produced PDGF and were responsible for 
the time-related increase in mitogen production after 
graft implantation. PDGF production by graft and 
aortic ECs and SMCs in vitro and in vivo was assessed 
by radioreceptor assay and immunohistochemical 
analysis, respectively, and PDGF gene expression was 
determined with reverse transcription linked with 
polymerase chain reaction (RT-PCR). These studies 
demonstrated that graft SMCs are distinctly different 
from aortic SMCs with respect to PDGF production, 
producing high levels of this mitogen. 
MATERIALS AND METHODS 
To evaluate PDGF production by ECs and 
SMCs, adult female beagles underwent placement of 
knitted Dacron thoracoabdominal grafts seeded with 
autologous jugular vein ECs. Five grafts were re- 
moved 20 weeks after implantation to assess PDGF 
production by cells in culture. To evaluate mRNA 
expression for PDGF A-chain, three grafts were re- 
moved 4 weeks after implantation and three grafts 
were removed after 20 weeks. In addition, graft sec- 
tions were examined using immunohistochemical 
analysis. Animals ranged in age from 71 to 199 weeks 
and weighed 7.5 to 12 kg. The mean age of dogs 
whose grafts were removed at 4 weeks and 20 weeks 
was not significantly different (165 + 19 weeks and 
138 _+ 22 weeks, respectively; p = 0.285). The pro- 
tocol for animal studies was approved by the institu- 
tional committee on animal use. Care complied with 
the "Principles of Laboratory Animal Care" and 
Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health publication No. 86- 
23, revised 1985). 
Graft implantation and removal. Cooley Dou- 
ble-Velour knitted Dacron grafts (Meadox Medicals 
Inc.; Oakland, N.J.), 6 mm internal diameter and 22 
cm long, were implanted as thoracoabdominal grafts 
as described previously, s Grafts were seeded with 
ECs enzymatically harvested from autologous exter- 
nal jugular veins and were added to the blood used to 
preclot he grafts. After 4 or 20 weeks the graft and 
native vessels were carefully isolated and flushed with 
medium 199 (M199) tissue culture medium (Sigma 
Chemical Co.; St. Louis). Tissue on the outer surface 
of the graft was removed uring the harvest. 
Cell harvest. Cells were harvested from the 
proximal aorta (ascending aorta and aortic arch) and 
the distal abdominal orta below the graft anastomo- 
sis. In addition, cells were isolated from four graft 
sections consisting of proximal anastomosis, proxi- 
mal midgraft, distal midgraft, and distal anastomosis. 
The anastomotic graft segments included 5 mm of 
the adjacent artery. The luminal surface was incu- 
bated in collagenase A (630 units/ml) for 10 min- 
utes at 37 ° C in a 5% CO 2 atmosphere, and ECs were 
removed mechanically using a rounded spatula. 
SMCs were harvested after removal of the EC 
layer from aortic and graft segments. The medial 
layer was removed mechanically, and the media and 
graft divided into 2 × 2 mm 2 pieces. The pieces were 
then incubated for 2 hours in an M199-based solu- 
tion containing 15 units/ml elastase type III (Sig- 
ma), 170 units/ml collagenase A, 2 mg/ml crystal- 
line bovine serum albumin (BSA; Boehringer 
Mannheim Biochemicals), 0.375 mg/ml soybean 
trypsin inhibitor (Boehringer Mannheim). SMCs 
were then collected, centrifuged at 300g for 5 min- 
utes, and resuspended in M199. The homogeneity of 
EC and SMC isolates was confirmed by immunohis- 
tochemical nalysis with antibody to von Willebrand 
factor (Chemicon International; Temecula, Calif.) 
and antibody to SMC ot-actin (Sigma). 
Cell culture. For analysis of PDGF production 
by ECs in primary culture, tissue culture plates were 
coated with fibronectin and ECs were grown to con- 
fluence in M199 containing 15 units/ml of heparin 
sodium, 0.15 mg/ml of endothelial cell growth sup- 
plement (ECGS) isolated from bovine hypothalami 
(Rockland; Gilbertsville, Pa.), 0.05 mg/ml ofgenta- 
micin (Sigma), 2.2 mg/ml of sodium bicarbonate, 
and 20% fetal bovine serum (FBS; Hyclone, Provo, 
Utah). After cells reached confluence, medium was 
changed to M199 with 5% FBS and collected after 72 
hours for measurement of PDGF production. 
SMCs were plated in FBS-coated tissue culture 
wells and grown to confluence in M199 with 20% 
FBS. The medium was then changed to M199 with 
5% FBS for PDGF collection. In addition, SMCs 
were passaged after incubation in a 0.05% trypsin 
solution for 5 minutes at 37 ° C. 
PDGF assay. The PDGF in conditioned me- 
dium was measured by radioreceptor assay as de- 
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scribed by Fox and DiCorleto, 9 which measures 
competition with t2SI-labeled PDGF for binding to 
PDGF receptors on human foreskin fibroblasts. 
Briefly, PDGF AB (Boehringer Mannheim) was ra- 
diolabeled according to the method of Heldin et al. 10 
Sparse, quiescent cultures of human foreskin fibro- 
blasts were incubated first with conditioned medium, 
then medium containing 12SI-labeled PDGF. Cell- 
bound radioactivity was determined in a gamma- 
radiation counter. A standard curve was prepared 
with known amounts of purified PDGF, and results 
were fit by nonlinear egression with the logistic 
equation. The PDGF production by graft and arterial 
cells was expressed as picograms PDGF per micro- 
gram DNA. 
DNA measurement. DNA in cultured cells was 
quantitated using the method escribed by Labarca 
and Paigen. 11 Briefly, cells were harvested with 
0.05% trypsin solution and lysed with a sonicator. 
The cell lysate (25 Ftl) was then diluted to 750 Ixl 
with phosphate/NaCl buffered solution (4 mol/L 
NaC1) and added to 750 ix1 of bis-benzamide solu- 
tion. Emission was measured with a fluorimeter with 
excitation set at 356 nm and emission set at 458 nm. 
The standard curve was prepared with stock calf 
thymus DNA (Sigma), and results were fit by nonlin- 
ear regression with the logistic equation. Results 
were expressed as ~g of DNA per well. 
mRNA isolation. To study gene expression, 
ECs and SMCs were harvested from grafts and arter- 
ies in three dogs at 4 weeks and three dogs at 20 
weeks after graft implantation. Isolation of polyA+ 
RIgA from ECs and SMCs was performed using the 
Micro-FastTrack mKNA Isolation Kit (Invitrogen 
Corp.; San Diego). Cells were lysed and the lysate 
applied to the oligo dT cellulose column. After high- 
and low-salt buffer washes, mRNA was eluted from 
the oligo dT cellulose column with a salt-ftee buffer, 
precipitated, and stored at -70 ° C in 100% ethanol. 
Polymerase chain reaction. The PDGF A-chain 
and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) mRNA from aortic ECs and SMCs were 
amplified using RT-PCR. Reverse transcriptase, ran- 
dom hexamers, and deoxynucleotides were used to 
synthesize complementary DNA (cDNA) from iso- 
lated mRNA. PDGF A-chain and GAPDH eDNA 
were selccrively amplified using specific primers, 12,13 
excess nucleotides, and a heat-stable DNA polymer- 
ase (Taq) for 30 cycles with a denaturing tempera- 
ture of 92 ° C, an annealing temperature of 58 ° C, 
and an extension temperature of 72 ° C. The RT- 
PCR products were separated on a 1% agarose gel 
and transferred to a GeneScreen nylon membrane (Du- 
pont NEN; Boston)? 40ligonucleotide probes, 12,13 la- 
beled with [32p] using the T4 polynucleofide ldnase 
method, Is were established as specific for PDGF A- 
chain and GAPDH in preliminary cxperimcnts, 
yielding a single, specific amplified product of the 
correct length. The Southern blots were hybridized 
overnight at 37 ° C, washed the following day, and 
exposed to I(odal~ XAR-5 film (Kodak; Rochester, 
N.Y.) or a phosphorimager screen. Comparison of 
gene expression was made possible by coamplifica- 
tion of the constitutively expressed gene GAPDH. 
Quantitative densitometry was performed on autora- 
diographs using radioactive [I4C] standards (Ameri- 
can Radiolabeled Chemicals, Inc.; St. Louis) or with 
a phosphorimager (Molecular Dynamics; Sunnyvale, 
Calif.). Results were expressed as a ratio of the PDGF 
signal to the GAPDH signal. 
Immunocytochemlcal analysis. Tissue sections 
were stained for PDGF A-chain and B-chain protein 
using specific antibodies (Santa Cruz Biotechnology, 
Inc.; Santa Cruz, Calif.). Fresh tissue was immersion- 
fixed in 2% paraformaldehyde/phosphate-buffered 
saline solution (PBS) for 5 hours and then was placed 
in 25% sucrose/PBS overnight. Tissue was then em- 
bedded in OCT compound, and 10 txm sections 
were cut with an AS620 cryotome (Shandon Lip- 
shaw, Inc.; Pittsburgh). Immunoperoxidase staining 
was performed using the Vectastain Elite ABC Kit 
(Vector Laboratories, Inc.; Burlingame, Calif.). To 
quench endogenous peroxidase activity, slides were 
placed in 0.3% H202 in methanol for 30 minutes. 
After rinsing with PBS/0.1% BSA, slides were incu- 
bated in blocking serum for 30 minutes to lessen 
nonspecific staining. Primary antibody against PDGF 
A-chain or B-chain was applied at a 1:100 dilution. 
The slides were incubated with biotinylated antirab- 
bit antibody and then with Vectastain ABC reagent 
for 30 minutes. Diaminobenzidine t trahydrochlo- 
ride (Polyscienees, Inc.; Warrington, Pa.) was used 
for the peroxidase enzyme substrate, and produced a 
reddish brown precipitate. Tissue was counterstained 
with Harris' hematoxylin stain without acetic acid 
(Richard-Allen Medical; Richland, Mich.). Controls 
included omission of the primary antibody and use of 
antibodies to PDGF A-chain and B-chain that had 
been preadsorbed with the respective ligand. 
RESULTS 
PDGF production by cultured cells. PDGF 
was mcasured in cells harvested from five dogs 20 
weeks after graft implantation. Because of the vari- 
ability in basal PDGF production bctwcen dogs, 
PDGF secretion (pg/ptg DNA) was normalized to 
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PDGF production by the ECs or SMCs harvested 
from arteries of the same dog. Pure primary EC 
cultures (n = 4) from graft and native aorta did not 
produce significantly different amounts of PDGF in 
72 hours, the normalized values (mean _+ SEM) 
being 1.04 _+ 0.18 and 1.06 -+ 0.22, respectively 
(Table I). Primary cultures of graft SMCs (n = 5) 
produced significantly more PDGF in 72 hours than 
aortic SMCs (3.26 _+ 0.84 and 1.06 -+ 0.33, respec- 
tively; p < 0.05; Table I). PDGF production by 
aortic SMCs proximal and distal to the graft was 
similar to that by aortic SMCs from dogs that did not 
undergo graft implantation. ~6
To assess the duration of altered mitogen secre- 
tion, PDGF production by SMCs was measured dur- 
ing multiple passages of cells harvested from three 
dogs. The conditioned medium from graft and aortic 
SMCs in primary culture, as well as passages 2, 4, 6, 
and 8, was collected and assayed for PDGF secretion. 
Graft SMC PDGF production remained greater than 
aortic SMC PDGF production through at least six 
cell passages (Table II). With increasing numbers of 
cell passages, graft SMC PDGF production de- 
creased whereas aortic SMC PDGF production in- 
creased, reaching nearly equivalent levels by passage 
8 (1.43 -+ 0.70 vs 0.59 +_ 0.21, graft and aortic 
SMCs respectively; p = 0.27). Thus graft SMCs 
produced significantly more PDGF than aortic 
SMCs, and this characteristic did not disappear rap- 
idly when both cell types were subjected to the same 
local environment ofcell culture. 
PDGF A-chain mRNA expression. One possi- 
ble explanation for the lack of difference in PDGF 
production by ECs is that they rapidly modulate in 
cell culture, resulting in loss of unique characteristics 
possessed in vivo. Therefore, as another method to 
identify the graft cells responsible for PDGF produc- 
tion and also to determine the level of regulation of 
PDGF secretion, ECs and SMCs were isolated from 
Dacron grafts 4 weeks (n = 3) and 20 weeks (n = 3) 
after implantation. Immunocytochemical analysis us- 
ing antibodies to yon Willebrand factor and e~-actin 
was used to verify the identity of the cells, mRNA was 
then isolated, and PDGF gene expression deter- 
mined using RT-PCR and represented as the ratio of 
PDGF A-chain signal to GAPDH signal (Fig. 1). 
PDGF gene expression was lower in Dacron graft 
ECs compared with aortic ECs at 4 weeks (0.90 -+ 
0.45 and 1.61 _+ 0.67, respectively) and at 20 weeks 
(4.15 -+ 0.38 and 6.38 _+ 1.36, respectively). On the 
other hand, graft SMCs expressed more PDGF A- 
chain mRNA than aortic SMCs at both 4 weeks 
(1.44 -+ 0.38 and 0.45 _+ 0.11, respectively) and 20 
Table I. Secretion of PDGF during 72 
hours in primary culture 
EC (n = 4) SMC (n = 5) 
Proximal aorta 0.86 -+ 0.07 1.34 ± 0.64 
Proximal anastomosis 0.99 -+ 0.17 2.74 ± 0.44 
Midgraft 1.10 -+ 0.25 4.27 -+ 1.24 
Distal anastomosis 1.54 _+ 0.40 2.01 _+ 0.51 
Distal aorta 1.48 -+ 0.57 1.06 ± 0.38 
Iliac artery 0.77 +_ 0.50 1.28 ± 0.57 
PDGF (pg/Ixg DNA) expressed as a ratio of mean PDGF secre- 
Lion by ECs or SMCs derived from native arteries in that dog. 
weeks (3.33 + 0.74 and 2.34 + 0.86, respectively). 
When results for both 4- and 20-week Dacron grafts 
were combined, PDGF A-chain gene expression was 
significantly higher for graft SMCs than aortic SMCs 
(2.44 + 0.67 and 1.45 + 0.57, respectively; p < 
0.05 by Wilcoxon signed rank). As seen in Fig. 2, the 
pattern of gene expression was consistent between 
dogs, with the mean ratio of graft to aortic PDGF 
A-chain/GAPDH RT-PCR signal being 0.62 + 
0.08 for ECs and 2.34 + 0.36 for SMCs. 
Immunocytochemical nalysis. To determine 
whether these changes in mRNA expression corre- 
lated with protein production i  vivo, immunohisto- 
chemical analyses for PDGF A-chain and B-chain was 
performed. ECs from both graft and aortic segments 
stained positively for PDGF A-chain and B-chain 
proteins in a diffuse and comparable manner (Figs. 3 
and 4). Both PDGF A-chain and B-chain were de- 
tected in SMCs from the graft segments, but in 
contrast, here was essentially no staining for PDGF 
A-chain or B-chain in SMCs of the native aorta (Figs. 
3 and 4). The graft SMCs that stained for PDGF 
were often located just beneath the endothelium. No 
intracellular staining was observed in negative con- 
trols. These results suggest that differences found in 
PDGF production in vitro reflect changes een in 
vivo, with graft SMCs producing more PDGF than 
aortic SMCs. 
DISCUSSION 
Previous studies uggested that PDGF produc- 
tion by endothelialized prosthetic grafts was higher 
than native artery or control grafts, but the actual 
cellular source of the PDGF was not identified. 4,s 
Results of the current study indicate that PDGF 
secretion by graft and aortic ECs is not significantly 
different and that PDGF production by ECs does not 
account for the higher levels of PDGF secreted from 
grafts segments compared with normal aorta. Al- 
though the similarity in PDGF secretion by graft and 
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Fig. 1. Southern blots of SMC and EC PDGF A-chain and GAPDH mRNA amplified by 
RT-PCR. Aortic and graft ECs and SMCs are from a representative dog. Images are computer- 
enhanced. A-chain/GAPDH numbers represent the ratios of signal intensities before enhance- 
ment. 
Table I I .  SMC Secretion o fPDGF (pg/Ixg DNA) during multiple passages 
PO P2 P4 P6 P8 
Proximal aorta 1.36 _+ 0.91 1.02 _+ 0.07 0.74 ± 0.20 0.63 _+ 0.22 0.42 _+ 0.34 
Proximal anastomosis 3.14 ± 0.24 4.67 _+.2.84 1.77 ± 0.40 2.80 _+ 1.68 0.85 _+ 0.53 
Midgraft 6.07 ± 1.01 17.18 -+ 5.22 6.79 ± 1.54 7.39 ± 2.06 2.15 _+ 1.93 
Distal anastomosis 2.78 _+ 0.29 7.12 +_ 2.31 4.43 ± 0.99 2.52 _+ 0.79 0.96 -+ 0.72 
Distal aorta 1.56 _+ 0.36 0.37 ± 0.19 1.08 -+ 0.14 0.66 -+ 0.10 0.77 +- 0.37 
Iliac artery 0.51 _+ 0.51 1.83 ± 0.56 0.74 ± 0.01 0.63 _+ 0.31 0.44 ± 0.21 
PDGF (pg/~g DNA) expressed asa ratio f mean PDGF secretion by SMCs derived from native arteries inthat dog (n = 3). 
aortic ECs cultured from 20-week animals might be 
a result of rapid EC modulation in primary passage 
causing cells to lose unique characteristics possessed 
in vivo, results of immunohistochemical analysis and 
RT-PCR suggest hat protein production and gene 
expression are similar in aortic and graft ECs in vivo. 
Development ofsubstantial subendothelial tissue, es- 
pecially 20 weeks after graft implantation, may mini- 
mize the "foreign" environment of the prosthetic 
graft, resulting in similar levels of mitogen produc- 
tion by both graft and aortic ECs. Although ECs on 
grafts produce PDGF, our findings suggest that ECs 
are not responsible for increased PDGF secretion 
found in 20-week grafts compared with 4-week 
grafts. 
SMCs from 20-week grafts produce significantly 
more PDGF than aortic SMCs in primary cell cul- 
ture. This characteristic persists through multiple 
passages, which suggests that it is not a transient 
effect of the local environment in the graft but that 
graft SMCs have altered synthetic machinery com- 
pared with aortic SMCs. Furthermore, findings with 
immunohistochemical analysis and RT-PCR indicate 
that graft SMCs in vivo produce more PDGF and 
express higher levels mRNA for PDGF A-chain than 
aortic SMCs. These findings arc consistent with 
those of Golden et al. 4 that documented higher levels 
of PDGF A-chain mRNA in graft neointima than 
aorta, but the cells expressing the PDGF gene were 
not identified in that study. Increased PDGF secre- 
tion by graft SMCs compared with aortic SMCs, 
combined with previous findings of  a time-related 
increase in SMC number in the prosthetic graft neo- 
intima, suggest hat the graft SMCs are responsible 
for the increased PDGF production by prosthetic 
grafts over time. 6,7 Furthermore, the RT-PCR data 
demonstrate hat the increased PDGF production in 
graft SMCs is regulated at the level of gene expres- 
sion (i.e., either increased gene transcription or 
mRNA stability). 
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Fig. 2. Graph of RT-PCR results hows PDGF A-chain/GAPDH signal intensity. Graft ECs 
express lower levels of PDGF A-chain mRNA than aortic ECs, whereas graft SMCs consistently 
express higher levels than aortic SMCs. 
The source of the SMCs on the graft is uncertain. 
They are probably not derived from the initially 
seeded cells, because jugular vein ECs maintained in
culture are rarely contaminated with SMCs. SMCs 
may grow onto the graft from the adjacent artery or 
by transinterstitial growth, perhaps stimulated by 
chemotactic factors produced by ECs. These two 
sources of SMCs may explain differences een in 
PDGF production by midgraft and anastomotic 
SMCs, with anastomotic SMCs producing levels of 
PDGF midway between midgraft and aortic SMCs. 
The elevated PDGF production by graft SMCs 
suggests that they are modulated to a secretory state, 
similar to SMCs found early in development or in 
pathologic states, such as atherosclerosis or inju- 
ry) 7-21 Neonatal SMCs secrete high levels of PDGF, 
but as they mature they change in phenotype and 
stop producing measurable quantities of PDGF. 22 In 
addition, the type of PDGF produced by SMCs ap- 
pears to be distinct for different stages of normal 
development, with rat pup SMCs expressing mRNA 
for A-chain and B-chain whereas uninjured adult rat 
SMCs express only mRNA for PDGF A-chain. 17 
In pathologic states such as athcrosclerosis or 
intimal hyperplasia, dult SMCs appear to be capable 
of reverting to a "fetal" phenotype, with altered 
PDGF gene expression and mitogen production. A1- 
though SMCs from normal arteries do not produce 
measurable quantities of PDGF, SMCs cultured 
from human atherosclerotic plaques produce PDGF 
and express mRNA for PDGF A-chain. 19 In situ 
hybridization studies demonstrate PDGF A-chain 
mRNA in the mesenchymal cells of atherosclerotic 
plaque, but not in normal artery. 2° Arterial injury in 
animal models also induces SMCs to revert to a 
juvenile state after injury, secreting PDGF and ex- 
pressing mRNA for PDGF A-chain and B-chain) 7,18 
These studies suggest hat mature SMCs retain the 
ability to modulate their phenotype after injury or in 
disease states to produce increased amounts of PDGF. 
Relatively little is known about changes in SMC 
phenotype and PDGF production or genc expression 
after prosthetic graft implantation. Birinyi et al. 21 
found that SMCs culturedfrom human graft hyper- 
plastic lesions express mRNA for PDGF A-chain and 
secrete a PDGF-like molecule. By immunohisto- 
chemical analysis, Kraiss et al. 23 demonstrated PDGF 
A-chain in the SMC layers immediately subjacent to 
the endothelial surface of grafts removed from ba- 
boons. These studies and our findings of significant 
differences in graft and arterial SMC production of 
PDGF suggest that SMCs on grafts are modulated to 
a phenotype similar to that found after injury or in 
atherosclerosis. 
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Fig. 3. Immunohistochemical analysis using antibody to 
PDGF A-chain (original magnification, ×400). Aortic sec- 
tion (A) has less staining of SMCs than graft section (B). 
Fig. 4. Immunohistochemical analysis using antibody to 
PDGF B-chain (original magnification, ×400). Aortic sec- 
tion (A) has less staining of SMCs than graft section (B). 
One possible explanation for the unique pheno- 
type of graft SMCs compared with aortic SMCs is 
that SMCs that migrate onto the graft represent a
small subpopulation of cells in the normal aorta that 
retain their proliferative and secretory capacity. In 
the bovine neonatal pulmonary artery, a distinct sub- 
population of SMCs proliferate in response to hyp- 
oxia. 24 Similarly, in balloon-injured rat carotid arter- 
ies, a subpopulation of intimal cells express mRNA 
for PDGF B-chain. 2s These cells are occasionally 
\ 
arranged in clusters, suggesting a common precur- 
sor. Perhaps after prosthetic graft implantation, a
subpopulation ofnormal arterial SMCs migrate onto 
the graft and proliferate there, and these cells are 
capable of secreting PDGF. If this is the case, how- 
ever, one would expect homogeneous staining for 
PDGF on immunohistochemical analysis, but in- 
stead there is a definite increase in the subendothelial 
SMCs, similar to that found by Kraiss et al. 23 Perhaps 
a more plausible explanation is that the SMCs that 
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migrate onto the graft and proliferate there are al- 
tered by the environment to express a secretory phe- 
notype, and this does not quickly revert to a contrac- 
tile phenotype. 
The production of PDGF may be important in 
the development of graft intimal hyperplasia for sev- 
eral reasons. If graft SMCs have the ability to re- 
spond to the PDGF they produce, continued prolif- 
eration may be stimulated in an autocrine fashion. 
Kraiss et al. 2s demonstrated PDGF receptor [3-sub- 
unit mRNA and protein, and lower levels of the 
(x-subunit mP, NA, in the neointima of grafts in ba- 
boons. Although the response of graft SMCs to 
PDGF was not studied, the expression of mRNA for 
PDGF receptor suggests that the SMCs are capable 
of responding to PDGF. On the other hand, if graft 
SMCs do not have the ability to respond to PDGF, 
production of this mitogen may contribute to ongo- 
ing SMC migration onto the graft, especially at the 
anastomoses. Work by others suggests that PDGF 
contributes to intimal hyperplasia after mechanical 
injury. Infusion of antibody to PDGF reduced the 
area ofneointimal hyperplasia by 40.9% after balloon 
catheter injury of rat carotid arteries by interfering 
with migration of medial SMCs into the neointima. 26 
Furthermore, increased amounts of PDGF, either by 
systemic infusion or gene transfer, 27,28 results in in- 
creased intimal thickening. Although these studies 
suggest hat PDGF plays a role in SMC accumulation 
in the intima, the pathophysiologic significance of 
PDGF in the production ofintimal hyperplasia or the 
mechanism by which altered SMC production of 
PDGF might contribute to intimal hyperplasia is 
uncertain. 
Our studies suggest hat SMCs that accumulate 
on prosthetic grafts are altered and have higher 
PDGF production and PDGF mRNA expression 
than aortic SMCs. Although graft healing in animal 
models is not identical to that in human beings, this 
altered phenotype in graft SMCs is similar to that 
seen in SMCs from human atherosclerotic lesions. If 
graft SMCs are also responsive to the effects of 
PDGF, autocrine growth stimulation may occur and 
contribute to the development of anastomotic inti- 
real hyperplasia in grafts. Understanding of the 
mechanism of increased PDGF production would 
provide insight into the cause of intimal hyperplasia 
and promote the development of strategies to pro- 
long graft patency. 
We gratefully acknowledge Meadox Medicals Inc., 
Oakland, N.J., for their donation of 6 mm internal diame- 
ter Cooley double-velour knitted Dacron grafts. 
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